NEWS
News Updates
Uniting Hearts and Combining Forces: Otaikang’s Internal Training Successfully Held
Release time:
2020-09-25 17:23
Source:
Unite our hearts and pool our strengths—our momentum will secure the future.
——Otaikang’s internal training was successfully held.
From June 2 to 3, 2018, the Otaikang Group held an internal training session in Beijing, themed “Unite Hearts and Pool Strengths for a Winning Future.”
Mr. Rao Yiwei, General Manager of Aotekang Group, delivered an inspiring opening address for the training session. To help participants gain a deeper understanding of the industry landscape, appreciate the company’s corporate culture and development plans, clarify their own roles and value propositions, and enhance their communication and self-management skills, this training program has specially invited a distinguished team of instructors: Mr. Rao Yiwei, Founder and General Manager; Ms. Yan Jiangwei, Director and Commercial Marketing Director; and Ms. Zhao Wenjing, Partner and Clinical Registration Manager. Drawing on the course materials, these experts provided detailed explanations and insightful sharing, progressing from basic concepts to more advanced topics. In particular, during the session titled “Industry Background and Corporate Planning,” Mr. Rao Yiwei, Founder and General Manager, highlighted how Aotekang’s MA solutions set it apart from other companies in the same field, and he also emphasized that the group’s equity incentive system was highly appealing to every participant attending the training.
After the three specialized training sessions concluded, the company invited six frontline employees to share their insights on specific topics. Grounded in their own roles, these employees consistently put the MA solution’s working philosophy into practice. They shared with everyone what they had learned and experienced in their daily work. They’ve not only witnessed the moon at two or three in the morning but have also seen the sun rise at four or five in the early hours of the morning. Thanks to their perseverance and hard work, they’ve continually reaped rewards and grown personally. Throughout the entire training session, participants remained highly engaged, and the frequent interactive activities kept the atmosphere buzzing with excitement and enthusiasm.
Finally, everyone took a bus to the R&D center and pilot-scale production base located in Gu'an, Hebei Province, and Daxing, Beijing. Dr. Wang, Director/Technical Director, gave a detailed introduction to the R&D laboratory and GMP-compliant production workshop of Aotekang Group’s CMO platform. As an essential component of Aotekang’s MA solutions, this platform not only undertakes research and development work for the Group’s key national 13th Five-Year Plan R&D projects but also supports the early-stage incubation and pilot-scale production of most biopharmaceutical and high-end medical device products.
In just a day and a half, through listening to the comprehensive yet targeted training provided by three lecturers, the participants deeply appreciated the tremendous potential for industry development and the vast opportunities our company offers. After hearing personal sharing from six employees, their conviction in growing together with the company became even stronger. A field visit to the company’s R&D center and pilot-scale testing facility further reinforced everyone’s sense of the company’s bright future. All participants expressed their determination to continue upholding the spirit of unity, collaboration, and relentless striving in their future work—loving their jobs, dedicating themselves wholeheartedly, and performing each task meticulously. They pledged to grow rapidly and achieve a win-win outcome: realizing both Otaikang’s goals and their own personal value!
Recommended Services
2020-09-25
Eurasia Huizhi boasts more than ten Phase I strategic collaboration centers, providing high-quality, specialized resources for early-phase clinical studies of innovative drugs. For each project, our expert medical team drafts initial clinical study protocols, consults with clinical experts in relevant fields, and develops clinically feasible and regulatory-compliant implementation plans. The company has extensive experience in conducting clinical trials for a variety of new drugs, including chemical drugs, traditional Chinese medicines, and biologics. Our services include: 1) Feasibility Assessment: Clinical trial feasibility evaluation, identification of centers/researchers, and center feasibility assessment & qualification review. 2) Medical and Clinical Strategy & Planning: Clinical trial planning & execution, risk identification & management.
2020-09-25
Opinions of the General Office of the State Council on Conducting Evaluations of the Quality and Efficacy Consistency of Generic Drugs (Guobanfa [2016] No. 8) Generic drugs that were approved for marketing prior to the implementation of the new classification system for chemical drug registration—and which have not been approved in accordance with the principle of consistency in quality and efficacy with the originator drugs—must undergo consistency evaluations. The consistency evaluation of generic drugs refers to the phased and batch-wise assessment of the quality consistency of generic drugs already approved for marketing, based on the principle of consistency in quality and efficacy with the originator drugs. In other words, generic drugs must achieve a level of quality and efficacy that is consistent with the originator drugs. The purpose of conducting these consistency evaluations is to ensure that generic drugs are comparable to the originator drugs in terms of both quality and efficacy.
Leave a message for inquiry
Follow us
Address: Room 3008, Building I, Yingkun Century, No. 6 Courtyard, East Road of the Automobile Museum, Fengtai District, Beijing
Phone: +86 10 86229816 Fax: 010-83739030
Email: bd-oyhz@healtech.com.cn (Business Cooperation)
ouyahuizhi-hr@healtech.com.cn (Resume Submission)
Follow the official account
WeChat Official Account
Friendship Links:Beijing Aotekang Pharmaceutical Technology Development Co., Ltd. Suzhou Suhao Biomaterials Technology Co., Ltd. Beijing Dikang Pharmaceutical Investment Management Co., Ltd. Center for Drug Evaluation, National Medical Products Administration National Medical Products Administration
Copyright © Eurasia Huizhi (Beijing) Medical Research Co., Ltd.